International Journal of Cancer Management

Published by: Kowsar

MiR-206 Target Prediction in Breast Cancer Subtypes by Bioinformatics Tools

Mahnaz Seifi-Alan 1 , Roshanak Shamsi 1 , Ali Behmanesh 2 , Reza Mirfakhraie 1 , Mir Davood Omrani 1 and Soudeh Ghafouri-Fard 1 , *
Authors Information
1 Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Iran University of Medical Sciences, Tehran, Iran
Article information
  • International Journal of Cancer Management: July 2018, 11 (7); e69554
  • Published Online: July 11, 2018
  • Article Type: Research Article
  • Received: April 21, 2018
  • Revised: May 12, 2018
  • Accepted: May 19, 2018
  • DOI: 10.5812/ijcm.69554

To Cite: Seifi-Alan M, Shamsi R, Behmanesh A, Mirfakhraie R, Omrani M D, et al. MiR-206 Target Prediction in Breast Cancer Subtypes by Bioinformatics Tools, Int J Cancer Manag. 2018 ; 11(7):e69554. doi: 10.5812/ijcm.69554.

Abstract
Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Ghafouri-Fard S, Shamsi R, Seifi-Alan M, Javaheri M, Tabarestani S. Cancer-testis genes as candidates for immunotherapy in breast cancer. Immunotherapy. 2014;6(2):165-79. doi: 10.2217/imt.13.165. [PubMed: 24491090].
  • 2. Dianatpour M, Mehdipour P, Nayernia K, Mobasheri MB, Ghafouri-Fard S, Savad S, et al. Expression of Testis Specific Genes TSGA10, TEX101 and ODF3 in Breast Cancer. Iran Red Crescent Med J. 2012;14(11):722-6. doi: 10.5812/ircmj.3611. [PubMed: 23396665]. [PubMed Central: PMC3560543].
  • 3. Iranpour M, Soudyab M, Geranpayeh L, Mirfakhraie R, Azargashb E, Movafagh A, et al. Expression analysis of four long noncoding RNAs in breast cancer. Tumour Biol. 2016;37(3):2933-40. doi: 10.1007/s13277-015-4135-2. [PubMed: 26409453].
  • 4. Kazemi-Oula G, Ghafouri-Fard S, Mobasheri MB, Geranpayeh L, Modarressi MH. Upregulation of RHOXF2 and ODF4 Expression in Breast Cancer Tissues. Cell J. 2015;17(3):471-7. [PubMed: 26464818]. [PubMed Central: PMC4601867].
  • 5. Sarrafzadeh S, Geranpayeh L, Tasharrofi B, Soudyab M, Nikpayam E, Iranpour M, et al. Expression Study and Clinical Correlations of MYC and CCAT2 in Breast Cancer Patients. Iran Biomed J. 2017;21(5):303-11. [PubMed: 28480695]. [PubMed Central: PMC5548962].
  • 6. Tasharrofi B, Soudyab M, Nikpayam E, Iranpour M, Mirfakhraie R, Sarrafzadeh S, et al. Comparative expression analysis of hypoxia-inducible factor-alpha and its natural occurring antisense in breast cancer tissues and adjacent noncancerous tissues. Cell Biochem Funct. 2016;34(8):572-8. doi: 10.1002/cbf.3230. [PubMed: 27862063].
  • 7. Soudyab M, Iranpour M, Ghafouri-Fard S. The Role of Long Non-Coding RNAs in Breast Cancer. Arch Iran Med. 2016;19(7):508-17. [PubMed: 27362246].
  • 8. Taherian-Esfahani Z, Abedin-Do A, Nouri Z, Mirfakhraie R, Ghafouri-Fard S, Motevaseli E. Lactobacilli Differentially Modulate mTOR and Wnt/ beta-Catenin Pathways in Different Cancer Cell Lines. Iran J Cancer Prev. 2016;9(3). e5369. doi: 10.17795/ijcp-5369. [PubMed: 27703648]. [PubMed Central: PMC5038836].
  • 9. Esfandiary A, Taherian-Esfahani Z, Abedin-Do A, Mirfakhraie R, Shirzad M, Ghafouri-Fard S, et al. Lactobacilli Modulate Hypoxia-Inducible Factor (HIF)-1 Regulatory Pathway in Triple Negative Breast Cancer Cell Line. Cell J. 2016;18(2):237-44. [PubMed: 27540529]. [PubMed Central: PMC4988423].
  • 10. Fu Y, Shao ZM, He QZ, Jiang BQ, Wu Y, Zhuang ZG. Hsa-miR-206 represses the proliferation and invasion of breast cancer cells by targeting Cx43. Eur Rev Med Pharmacol Sci. 2015;19(11):2091-104. [PubMed: 26125274].
  • 11. Zhou J, Tian Y, Li J, Lu B, Sun M, Zou Y, et al. miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem Biophys Res Commun. 2013;433(2):207-12. doi: 10.1016/j.bbrc.2013.02.084. [PubMed: 23466356].
  • 12. Muniategui A, Pey J, Planes FJ, Rubio A. Joint analysis of miRNA and mRNA expression data. Brief Bioinform. 2013;14(3):263-78. doi: 10.1093/bib/bbs028. [PubMed: 22692086].
  • 13. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207-10. [PubMed: 11752295]. [PubMed Central: PMC99122].
  • 14. Li L, Xu J, Yang D, Tan X, Wang H. Computational approaches for microRNA studies: a review. Mamm Genome. 2010;21(1-2):1-12. doi: 10.1007/s00335-009-9241-2. [PubMed: 20012966].
  • 15. Reyes-Herrera PH, Ficarra E. One decade of development and evolution of microRNA target prediction algorithms. Genomics Proteomics Bioinformatics. 2012;10(5):254-63. doi: 10.1016/j.gpb.2012.10.001. [PubMed: 23200135]. [PubMed Central: PMC5054202].
  • 16. Team RC. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014.
  • 17. Pathan M, Keerthikumar S, Ang CS, Gangoda L, Quek CY, Williamson NA, et al. FunRich: An open access standalone functional enrichment and interaction network analysis tool. Proteomics. 2015;15(15):2597-601. doi: 10.1002/pmic.201400515. [PubMed: 25921073].
  • 18. Zhang L, Liu X, Jin H, Guo X, Xia L, Chen Z, et al. miR-206 inhibits gastric cancer proliferation in part by repressing cyclinD2. Cancer Lett. 2013;332(1):94-101. doi: 10.1016/j.canlet.2013.01.023. [PubMed: 23348698].
  • 19. Yan D, Dong Xda E, Chen X, Wang L, Lu C, Wang J, et al. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem. 2009;284(43):29596-604. doi: 10.1074/jbc.M109.020511. [PubMed: 19710019]. [PubMed Central: PMC2785592].
  • 20. Singh A, Happel C, Manna SK, Acquaah-Mensah G, Carrerero J, Kumar S, et al. Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest. 2013;123(7):2921-34. doi: 10.1172/JCI66353. [PubMed: 23921124]. [PubMed Central: PMC3696551].
  • 21. Alteri A, De Vito F, Messina G, Pompili M, Calconi A, Visca P, et al. Cyclin D1 is a major target of miR-206 in cell differentiation and transformation. Cell Cycle. 2013;12(24):3781-90. doi: 10.4161/cc.26674. [PubMed: 24107628]. [PubMed Central: PMC3905070].
  • 22. Georgantas R3, Streicher K, Luo X, Greenlees L, Zhu W, Liu Z, et al. MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D. Pigment Cell Melanoma Res. 2014;27(2):275-86. doi: 10.1111/pcmr.12200. [PubMed: 24289491].
  • 23. Mataki H, Seki N, Chiyomaru T, Enokida H, Goto Y, Kumamoto T, et al. Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma. Int J Oncol. 2015;46(3):1039-50. doi: 10.3892/ijo.2014.2802. [PubMed: 25522678].
  • 24. Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol. 2007;21(5):1132-47. doi: 10.1210/me.2007-0022. [PubMed: 17312270].
  • 25. Samaeekia R, Adorno-Cruz V, Bockhorn J, Chang YF, Huang S, Prat A, et al. miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway. Clin Cancer Res. 2017;23(4):1091-103. doi: 10.1158/1078-0432.CCR-16-0943. [PubMed: 27435395]. [PubMed Central: PMC5247402].
  • 26. Sharma SB, Lin CC, Farrugia MK, McLaughlin SL, Ellis EJ, Brundage KM, et al. MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1. Mol Cell Biol. 2014;34(22):4143-64. doi: 10.1128/MCB.00480-14. [PubMed: 25202123]. [PubMed Central: PMC4248710].
  • 27. Liang Z, Bian X, Shim H. Downregulation of microRNA-206 promotes invasion and angiogenesis of triple negative breast cancer. Biochem Biophys Res Commun. 2016;477(3):461-6. doi: 10.1016/j.bbrc.2016.06.076. [PubMed: 27318091]. [PubMed Central: PMC4955785].
  • 28. Yin K, Yin W, Wang Y, Zhou L, Liu Y, Yang G, et al. MiR-206 suppresses epithelial mesenchymal transition by targeting TGF-beta signaling in estrogen receptor positive breast cancer cells. Oncotarget. 2016;7(17):24537-48. doi: 10.18632/oncotarget.8233. [PubMed: 27014911]. [PubMed Central: PMC5029720].
  • 29. Han H, Chen Y, Cheng L, Prochownik EV, Li Y. microRNA-206 impairs c-Myc-driven cancer in a synthetic lethal manner by directly inhibiting MAP3K13. Oncotarget. 2016;7(13):16409-19. doi: 10.18632/oncotarget.7653. [PubMed: 26918941]. [PubMed Central: PMC4941324].
  • 30. Elliman SJ, Howley BV, Mehta DS, Fearnhead HO, Kemp DM, Barkley LR. Selective repression of the oncogene cyclin D1 by the tumor suppressor miR-206 in cancers. Oncogenesis. 2014;3. e113. doi: 10.1038/oncsis.2014.26. [PubMed: 25111862]. [PubMed Central: PMC5189965].
  • 31. Bose S, Tholanikunnel TE, Reuben A, Tholanikunnel BG, Spicer EK. Regulation of nucleolin expression by miR-194, miR-206, and HuR. Mol Cell Biochem. 2016;417(1-2):141-53. doi: 10.1007/s11010-016-2721-2. [PubMed: 27221739].
  • 32. Amir S, Simion C, Umeh-Garcia M, Krig S, Moss T, Carraway K3, et al. Regulation of the T-box transcription factor Tbx3 by the tumour suppressor microRNA-206 in breast cancer. Br J Cancer. 2016;114(10):1125-34. doi: 10.1038/bjc.2016.73. [PubMed: 27100732]. [PubMed Central: PMC4865973].
  • 33. Lin CC, Sharma SB, Farrugia MK, McLaughlin SL, Ice RJ, Loskutov YV, et al. Kruppel-like factor 4 signals through microRNA-206 to promote tumor initiation and cell survival. Oncogenesis. 2015;4. e155. doi: 10.1038/oncsis.2015.8. [PubMed: 26053033]. [PubMed Central: PMC4753526].
  • 34. Wang J, Tsouko E, Jonsson P, Bergh J, Hartman J, Aydogdu E, et al. miR-206 inhibits cell migration through direct targeting of the actin-binding protein coronin 1C in triple-negative breast cancer. Mol Oncol. 2014;8(8):1690-702. doi: 10.1016/j.molonc.2014.07.006. [PubMed: 25074552]. [PubMed Central: PMC5528580].
  • 35. Ge X, Lyu P, Cao Z, Li J, Guo G, Xia W, et al. Overexpression of miR-206 suppresses glycolysis, proliferation and migration in breast cancer cells via PFKFB3 targeting. Biochem Biophys Res Commun. 2015;463(4):1115-21. doi: 10.1016/j.bbrc.2015.06.068. [PubMed: 26093295].
  • 36. Esfandiary A, Ghafouri-Fard S. MAGE-A3: an immunogenic target used in clinical practice. Immunotherapy. 2015;7(6):683-704. doi: 10.2217/imt.15.29. [PubMed: 26100270].
  • 37. Esfandiary A, Ghafouri-Fard S. New York esophageal squamous cell carcinoma-1 and cancer immunotherapy. Immunotherapy. 2015;7(4):411-39. doi: 10.2217/imt.15.3. [PubMed: 25917631].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments